Lupus Tumidus Without Severe Skin Lesions: What to Do When Mepacrine-Based Combination Therapy Has Not Achieved Adequate Improvement

This protocol is for patients with lupus tumidus who do not have severe or disseminated cutaneous lupus erythematosus skin lesions, and whose previous mepacrine-based antimalarial combination regimen did not produce the expected skin improvement within the anticipated timeframe.

Patient scenario Lupus tumidus in the absence of severe or disseminated cutaneous lupus erythematosus skin lesions — a localised presentation that has not responded sufficiently to the previous treatment step.

Prior treatment — insufficient response The preceding step involved Mepacrine in combination with hydroxychloroquine or chloroquine. Escalation to this protocol is indicated when that combination fails to achieve improvement of skin lesions within 3–4 weeks, with maximum effects typically expected after 6–8 weeks of treatment.

Next-line approach When the prior antimalarial-based combination has not produced adequate skin improvement, a systemic second-line agent is considered — potentially in combination with continued antimalarial therapy and a supportive co-medication. The complete regimen, sequencing, and follow-up plan are available in the full structured protocol.

Treatment goal: Improvement of cutaneous lupus erythematosus disease activity, assessed after 3–6 months of treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

Topical glucocorticoids are recommended for treating circumscribed CLE lesions.

MTX is recommended as a systemic second-line treatment at doses of up to 25 mg per week, and if possible in combination with antimalarial drugs.

During MTX treatment, a single oral dose of 5 mg folic acid should be given on the next day to reduce possible side effects.

Weekly doses of 15 mg and above are usually tolerated better if applied subcutaneously.

It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).

View source ↗